In its fifth time at bat in trials over injuries allegedly caused by the osteoporosis drug Fosamax, Merck & Co. on Monday knocked out the case of former airline pilot Linda Secrest, who blamed her severe jaw and dental problems on seven years of treatment with the drug.
The jury verdict is the fourth trial win for Merck and its third defense verdict in bellwether cases selected in federal multidistrict litigation over the drug. The company is still facing about 1,650 suits filed by Fosamax plaintiffs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
